Dabrafenib is a BRAF inhibitor used in the treatment of metastatic melanoma with BRAF V600E mutations. It works by inhibiting the abnormal BRAF protein that promotes cancer cell growth. Often used in combination with other therapies, it can also be used for non-small cell lung cancer and thyroid cancer.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Dabrafenib and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Dabrafenib impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Dabrafenib-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
